Pharmaceutical Industry - Publications - Faculty & Research - Harvard Business School

Filter Results: (926)

Filter Results: (926)

Show Results For

← Page 12 of 926 Results →

July 2010
Case

Metabical: Positioning and Communications Strategy for a New Weight Loss Drug

By: John A. Quelch and Heather Beckham

Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details

Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States

February 2009 (Revised December 2009)
Case

Merck: Global Health and Access to Medicines

By: V. Kasturi Rangan and Katharine Lee

The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details

Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry

July 2004 (Revised May 2005)
Case

Pfizer's Virtual CIO (Abridged)

By: F. Warren McFarlan and Brian DeLacey

Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent... View Details

Keywords: Decision Making; Cost Management; Organizational Culture; Strategy; Information Technology; Pharmaceutical Industry

Find at Harvard

March 2008 (Revised June 2008)
Case

Sirtris Pharmaceuticals: Living Healthier, Longer

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details

Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry

July 1989 (Revised December 1990)
Case

CIBA-GEIGY Pharmaceuticals: Pharma International

By: John A. Quelch

Examines the decision by Pharma International on whether to launch an antimalarial product in Nigeria and, if so, how that should be implemented. Involves commercial, ethical, and policy considerations. Rich in situation assessment data, the case refers to criticism of... View Details

Keywords: Ethics; Decision Choices and Conditions; Product Launch; Policy; Developing Countries and Economies; Pharmaceutical Industry; Nigeria

January 2016 (Revised January 2019)
Case

The Allergan Board Under Fire (A)

By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane

In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details

January 2016 (Revised January 2019)
Supplement

The Allergan Board Under Fire (B)

By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane

In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details

April 2008 (Revised May 2009)
Case

Robert Wessman and Actavis' "Winning Formula"

Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with 11,000 people, active in 40 countries, global manufacturing, and $1.6 billion.... View Details

Keywords: Globalized Firms and Management; Business Growth and Maturation; Success; Transformation; Business Strategy; Pharmaceutical Industry; Iceland

Article

One Obstacle to Curing Cancer: Patient Data Isn't Shared

By: Richard G. Hamermesh and Kathy Giusti

Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details

Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States

Register to Read

November 2006
Case

Selling Biovail Short

By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia

Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details

Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada

June 2004
Case

Aventis SA (A): Planning for a Merger

By: Joshua D. Margolis and Carin-Isabel Knoop

Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must... View Details

Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States

November 2016 (Revised February 2017)
Case

CVS Health: Redefining the Value Proposition

By: Michael E. Porter, Jorge Ramirez-Vallejo and Alexandra Houghtalin

This case explores how a company can use shared value as a lens to think about competition and strategy choices in a challenging and evolving industry. The case takes a historical look at the structure of the retail pharmacy industry and the changing nature of rivalry... View Details

Keywords: Shared Value; Pharmacy; Health Care; Strategy; Competitive Strategy; Retail Industry; Retail Industry; United States

September 2012
Case

SCMS: Battling HIV/AIDS in Africa

By: Ananth Raman, Noel Watson, Santiago Kraiselburd and Emmanuel Akili

In 2005, USAID and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), created the Supply Chain Management System (SCMS) to procure and distribute essential medicines and supplies; provide technical assistance to transform existing supply chains; and... View Details

Open Innovation – How can I use the crowd?

Innovation has become an urgent imperative for entrepreneurial and established organizations. Over the last decade, in industries as diverse as fashion design, media software, life sciences, pharmaceuticals and automotive, the most cutting edge organizations have... View Details

15 Jan 2008
First Look

First Look: January 15, 2008

organizational studies research. We empirically assess this assertion by analyzing studies of negotiation published in top peer-reviewed management, psychology, sociology, and industrial relations journals from 1990 to 2005. Our findings... View Details

Keywords: Martha Lagace

August 2013
Teaching Plan

Remicade-Simponi

By: Guhan Subramanian and Charlotte Krontiris

This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details

Keywords: Johnson ＆ Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry

December 2008 (Revised April 2010)
Case

Proteus Biomedical: Making Pigs Fly

By: Richard G. Hamermesh, Lauren Barley and Ginger Graham

Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is... View Details

Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Health Industry; Health Industry; Health Industry

August 2013 (Revised October 2013)
Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details

Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Australia; Europe; London

January 2001 (Revised May 2003)
Case

Novartis Pharma: The Business Unit Model

By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis

In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details

Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Health Industry; Health Industry

February 1996
Case

Chadwick, Inc.: The Balanced Scorecard (Abridged)

By: Robert S. Kaplan

The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details

Keywords: Balanced Scorecard; Research and Development; Product Launch; Commercialization; Consumer Behavior; Customer Focus and Relationships; Performance Evaluation; Pharmaceutical Industry

←
12
13
…
46
47
→